Longeveron Inc. Class A (LGVN)
NASDAQ: LGVNHealth CareBiotechnology: Pharmaceutical PreparationsUSD
Market open · Delayed 15 min · as of Oct 9, 9:47 AM ET
LGVN stock chart
Technical analysisKey statistics
All statistics- Market cap
- $7.57M
- EPS (TTM)
- -$9.90
- Dividend yield
- None
- 52-week range
- 2.30 – 12.30
- Day range
- 2.35 – 2.47
- Volume / Avg
- 5.02K / 92.38K
- Beta
- —
- Shares outstanding
- 3.04M
- Next earnings
- Nov 3, 2026
52-week range
LGVN stock today
Shares of Longeveron (LGVN) are trading higher on Oct 9 at $2.38, a gain of 0.21% or $0.005 per share, versus the S&P 500's 0.25% gain. Shares are 80.7% below their 52-week high of $12.30 and 3.3% above the 52-week low of $2.30, near the bottom of the past year's range. Longeveron has posted a net loss over the last twelve months (EPS of -$9.90), so its P/E ratio is not meaningful.
Longeveron's next earnings report is expected on Nov 3, 2026.
Summary generated from market data by MetaCap's automated system. Methodology
About Longeveron
Company profileLongeveron Inc., a clinical stage biotechnology company, develops cellular therapies for aging-related and life-threatening conditions in the United States. Its lead investigational product is the LOMECEL-B, an allogeneic mesenchymal stem cell formulation sourced from the bone marrow of young and healthy adult donors which is in phase 3 clinical trial to treat hypoplastic left heart syndrome; completed phase 2a clinical trial to treat Alzheimer's disease, as well as in phase 2b clinical trial to treat aging frailty. The company was incorporated in 2014 and is headquartered in Miami, Florida.
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- CEO
- Mr. Stephen H. Willard Esq.
- Headquarters
- Miami, FL
- Employees
- 38
- IPO year
- 2021
- Website
- longeveron.com
Analyst forecast
ForecastConsensus (2 analysts)
none
Avg. price target
$61.25+2478.95%
- Strong buy 0
- Buy 1
- Hold 1
- Sell 0
- Strong sell 0
Target range
Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.
Earnings
Earnings history- Next report
- Nov 3, 2026
- EPS estimate
- $-1.70
LGVN news
All LGVN newsLongeveron peers
Health Care sector| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| SNGXSoligenix Inc. | 0.3501 | +0.99% | $7.62M | vs LGVN |
| SKYESkye Bioscience Inc. | 1.69 | +0.60% | $7.48M | vs LGVN |
| INMInMed Pharmaceuticals Inc. | 1.39 | +4.51% | $7.64M | vs LGVN |
| FBLGFibroBiologics Inc. | 1.12 | +1.04% | $7.80M | vs LGVN |
| CNSPCNS Pharmaceuticals Inc. | 5.35 | 0.00% | $7.82M | vs LGVN |
| CURXCuranex Pharmaceuticals Inc | 4.61 | -3.15% | $7.23M | vs LGVN |
| AZTRAzitra Inc | 0.1301 | -0.15% | $7.88M | vs LGVN |
| APUSApimeds Pharmaceuticals US Inc. | 5.23 | -3.53% | $7.90M | vs LGVN |
Indexes, lists and sector
Longeveron stock FAQ
What is Longeveron's stock price today?
LGVN last traded at $2.38 as of Oct 9, 9:47 AM EDT, up 0.21% on the day. Prices are delayed at least 15 minutes.
When is Longeveron's next earnings date?
Longeveron is expected to report earnings on Tuesday, November 3, 2026. Analysts expect EPS of $-1.70.
Who is Longeveron's CEO?
Mr. Stephen H. Willard Esq. is the chief executive officer of Longeveron Inc. Class A, which has about 38 employees.
What is the LGVN 52-week high?
The 52-week high for LGVN is $12.30 and the 52-week low is $2.30. The stock is currently 80.7% below its high.